scispace - formally typeset
B

Brigitte Simon

Researcher at French Institute of Health and Medical Research

Publications -  19
Citations -  420

Brigitte Simon is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Cancer & Stem cell. The author has an hindex of 10, co-authored 19 publications receiving 343 citations. Previous affiliations of Brigitte Simon include University of Western Brittany.

Papers
More filters
Journal ArticleDOI

MicroRNA and targeted mRNA expression profiling analysis in human colorectal adenomas and adenocarcinomas

TL;DR: It is confirmed that several miRNAs were abnormally expressed in colorectal lesions, identified new deregulated miRs, and showed that severalmiRNAs could mark the transition from NOR to CRA, thereby marking progression from the early steps of cancer.
Journal ArticleDOI

A gene expression and pre-mRNA splicing signature that marks the adenoma-adenocarcinoma progression in colorectal cancer.

TL;DR: Four intersectional transcriptional signatures that could distinguish CRAs from normal mucosae or CRCs are identified, including a signature of 40 genes differentially deregulated in both CRA and CRC samples, which may mark the risk of cancer occurrence from analysis of CRA biopsies.
Journal ArticleDOI

Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells

TL;DR: The occurrence of marked phenotypic differences between HT29- and HCT116-drug resistant cells indicates that the acquired resistance depends mostly on the parental cell characteristics, rather than on the drug type used.
Journal ArticleDOI

Human caspase 7 is positively controlled by SREBP-1 and SREBP-2.

TL;DR: The results show that caspase 7, as an SREBP-1/2 target, can be induced under mevalonate-restricting conditions, which might help overcome its shortage.
Journal ArticleDOI

The association of statins and taxanes: an efficient combination trigger of cancer cell apoptosis.

TL;DR: The association of Lovastatin and docetaxel, or lovastatin alone, shows promise as plausible anticancer strategies, either as a direct therapeutic approach or following acquired P-glycoprotein-dependent resistance.